TXMD 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-11

• Other income, net. During the second quarter of 2026, we had other income of $980 thousand compared to other income of $1,240 thousand in the second quarter of 2025, reflecting a decrease in other income pertaining to Mayne’s royalty sales of ANNOVERA and amounts received in May 2025 in connection w…

• Six months ended June 30, 2026 compared with six months ended June 30, 2025

• The following table sets forth the results of our operations (in thousands):

• Income (loss) from continuing operations before income taxes 267 (123 )

• Income (loss) from continuing operations, net of income taxes 267 (91 )

相对上期删除的文字 · 来源:10-Q · 2026-05-12

• Other income, net. During the first quarter of 2026, we had other income of $826 thousand compared to other income of $613 thousand in the first quarter of 2025, reflecting an increase in sublease income and higher other income pertaining to Mayne’s royalty sales of ANNOVERA in the first quarter of …

• Our primary use of cash is to fund our continued operations. We have funded our operations primarily through revenue from licensed royalties, public offerings of our common stock and private placements of equity and debt securities, and the transactions with Mayne Pharma. As of March 31, 2026, we ha…